Pharmaceutical Industry
Filter News
Found 10,999 articles
-
With a patient-centric focus, Ipsen Biopharmaceuticals is on a mission to improve patients’ lives, leveraging its global reach and placing a strategic focus on external innovation.
-
AstraZeneca is attempting to find encouraging news in the failure of its MYSTIC clinical trial, but it doesn’t look good.
-
If the company does sell some older assets, it could use the funds to support development of high-growth assets in immuno-oncology.
-
Two pharmaceutical companies and a medtech maker snagged three of the top-10 spots on Deloitte’s 2018 North America Technology Fast 500, a ranking of the fastest-growing North American companies in the fields of technology, life sciences, telecommunications, media and energy.
-
November 16 Research Roundup: Obesity and Pancreatic Cancer, the Mighty Mitochondria, and Weightl...
11/16/2018
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them. -
In announcing the round, Camel-IDS said the finances will be used for a phase Ib/II trial of its lead program CAM-H2, a treatment option in HER2-positive cancers, while further developing preclinical programs and broadening the pipeline.
-
Vyera Pharmaceuticals Receives FDA Clearance To Initiate A Phase 1 Study Of A New Chemical Entity Designed As A Potential Treatment For Toxoplasmosis
11/16/2018
Vyera Pharmaceuticals, LLC announced it plans to initiate a Phase 1 single ascending dose (SAD) study of VYR-006, a novel dihydrofolate reductase (DHFR) inhibitor which Vyera discovered and is developing for the treatment of toxoplasmosis.
-
AVITA Medical Announces Hiring of Full U.S. Sales Team of Experienced Burn Professionals to Support National Launch of RECELL® System
11/16/2018
Strong market response to the RECELL System approval in advance of U.S. launch with 32 burn centers actively reviewing the product or placing commercial orders
-
Secarna Pharmaceuticals and MetP Pharma enter into a co-development agreement for transnasally delivered antisense oligonucleotide-based CNS therapeutics
11/16/2018
Secarna’s proprietary antisense oligonucleotide platform LNAplusTM to be combined with MetP Pharma’s nasal drug delivery technology to develop novel treatment options for neurodegenerative diseases
-
One Busy Week for AbbVie: Hepatitis C, Fibroids, Alzheimer’s & Parkinson’s, and Generic Criticism
11/15/2018
AbbVie presented additional data from two Phase III clinical trials in women with uterine fibroids. In a big news week for the company, what else is AbbVie up to? -
Boehringer Ingelheim and Epizyme Ink Collaboration Deal With $15 Million up Front and $280 Millio...
11/15/2018
Boehringer Ingelheim and Epizyme signed a global collaboration deal to identify, develop and market cancer therapies. The deal could exceed $300 million. -
Novartis has been on something of a housecleaning binge since Vasant (Vas) Narasimhan took over the chief executive officer position from Joseph Jimenez in January of this year. On October 30, Novartis indicated it planned to abandon approximately 20 percent of its research projects.
-
It has been a busy month for San Francisco-based Nektar Therapeutics. It started with a partnership to pair its lead drug candidate with one developed by pharma giant Pfizer. On Wednesday, the company named a Genentech veteran to helm its oncology programs.
-
Arena Pharmaceuticals Snags $800 Million from United Therapeutics for a Phase III PAH Drug
11/15/2018
United Therapeutics bets a significant amount of money on the potential commercialization of ralinepag. -
Cadent Therapeutics secured $40 million to advance its lead program, CAD-1883.The company also struck a deal with Novartis to develop NMDA modulators.
-
Prometic Reports Third Quarter 2018 Financial Results and Highlights
11/15/2018
Extension of maturity dates of Line of Credit and OID Loans to September 2024
-
China Pharma Holdings, Inc. Reports Third Quarter 2018 Financial Results
11/15/2018
China Pharma Holdings, Inc. announced today its financial results for the quarter ended September 30, 2018.
-
Oragenics, Inc. Receives Clearance to Enroll Patients in Germany and the United Kingdom into Its Phase 2 Clinical Trial of AG013 for Oral Mucositis
11/15/2018
Oragenics, Inc. today announced it has received clearance to enroll patients residing in Germany from the Paul Erlich Institute and patients residing in the United Kingdom from the Medicines and Healthcare products Regulatory Agency (MHRA), into its Phase 2 clinical trial of AG013, a live biotherapeutic product for the potential prevention and treatment of OM.
-
Cadent Therapeutics Secures $40 Million Series B Financing to Advance Pipeline of Novel Therapies for Movement and Cognitive Disorders
11/15/2018
Supports Near-term Initiation of Phase 2 Essential Tremor and Spinocerebellar Ataxia Trials
-
Oragenics, Inc. Announces 3Q 2018 Financial Results and Provides Corporate Update
11/15/2018
Oragenics, Inc. announced financial results for the quarter ended September 30, 2018.